Shuttle Pharmaceuticals Holdings, Inc. (SHPH) — SEC Filings
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) — 50 SEC filings. Latest: 8-K (Dec 29, 2025). Includes 36 8-K, 5 S-1, 4 10-Q.
View Shuttle Pharmaceuticals Holdings, Inc. on SEC EDGAR
Overview
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 29, 2025: Shuttle Pharmaceuticals Holdings, Inc. entered into a material definitive agreement on December 23, 2025. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing date was December 29, 2025.
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant filing sentiment for Shuttle Pharmaceuticals Holdings, Inc. is neutral.
Filing Type Overview
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) has filed 36 8-K, 3 S-1/A, 5 S-1, 4 10-Q, 1 DEF 14A, 1 10-K with the SEC between Sep 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of SHPH's 47 recent filings, 9 were flagged as high-risk, 33 as medium-risk, and 5 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$9.1M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $2.09M |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Christopher Cooper
- Zhitian (Andy) Zhang
- Connor Yuen
- Ross Carmel
- Jeff Cahlon
- Dr. Robert L. J. van der Laan
- Dr. David M. Epstein
- Anatoly Dritschilo, M.D.
Industry Context
The pharmaceutical and biotechnology industry is increasingly leveraging artificial intelligence and machine learning for drug discovery and development. Companies are seeking to accelerate the identification of novel drug candidates and optimize preclinical research through advanced computational platforms. The competitive landscape includes established pharmaceutical giants and a growing number of specialized AI-driven biotech firms.
Top Tags
material-agreement (10) · pharmaceuticals (7) · material-definitive-agreement (6) · equity-sale (5) · financials (5) · Biotechnology (4) · regulatory-filing (4) · filing (4) · leadership-change (4) · corporate-governance (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Shares of common stock | 625,156 | Issuable upon exercise of a pre-funded warrant for resale by selling stockholder |
| Exercise price per share | $0.001 | Nominal exercise price for the pre-funded warrant |
| Aggregate gross proceeds | $2.5 million | Received by the Company from the private placement on November 4, 2025 |
| Last reported sale price for common stock | $1.85 | On December 10, 2025, listed on The Nasdaq Capital Market |
| Cash fee | 4% | Paid to WestPark Capital, Inc. for placement agency services |
| Reverse stock split | 1-for-25 | Effected on June 16, 2025 |
| Acquisition date | November 21, 2025 | Date Molecule.ai assets and liabilities were acquired |
| Discontinuance date | November 20, 2025 | Date the Company committed to discontinue Ropidoxuridine clinical trials |
| Private placement closing date | November 4, 2025 | Date the private placement of pre-funded warrant closed |
| Beneficial ownership limit | 4.99% | Maximum percentage of outstanding common stock the warrant holder can own upon exercise |
| Last reported sale price per share | $1.92 | For SHPH common stock on November 17, 2025 |
| Shares of common stock outstanding | 1,603,285 | As of November 17, 2025 |
| Commencement date | October 2024 | For the Phase II clinical study of Ropidoxuridine in brain cancer patients |
| Closing date | November 4, 2025 | For the private placement of the pre-funded warrant |
| Date of binding term sheet | October 20, 2025 | For the contemplated asset acquisition from 1542770 BC Ltd. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Shuttle Pharmaceuticals Holdings, Inc. (SHPH)?
Shuttle Pharmaceuticals Holdings, Inc. has 50 recent SEC filings from Sep 2024 to Dec 2025, including 36 8-K, 5 S-1, 4 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of SHPH filings?
Across 50 filings, the sentiment breakdown is: 8 bearish, 41 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Shuttle Pharmaceuticals Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Shuttle Pharmaceuticals Holdings, Inc. (SHPH) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Shuttle Pharmaceuticals Holdings, Inc.?
Key financial highlights from Shuttle Pharmaceuticals Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for SHPH?
The investment thesis for SHPH includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Shuttle Pharmaceuticals Holdings, Inc.?
Key executives identified across Shuttle Pharmaceuticals Holdings, Inc.'s filings include Christopher Cooper, Zhitian (Andy) Zhang, Connor Yuen, Ross Carmel, Jeff Cahlon and 3 others.
What are the main risk factors for Shuttle Pharmaceuticals Holdings, Inc. stock?
Of SHPH's 47 assessed filings, 9 were flagged high-risk, 33 medium-risk, and 5 low-risk.
What are recent predictions and forward guidance from Shuttle Pharmaceuticals Holdings, Inc.?
Forward guidance and predictions for Shuttle Pharmaceuticals Holdings, Inc. are extracted from SEC filings as they are enriched.